top of page

Oncology Nursing Showdown! 0.5 CNE

FREE Offering! Click here to check it out!


Each year, 81,560 new cases of non-Hodgkin lymphoma (NHL) are diagnosed, and 20,720 people die of the disease (American Cancer Society, 2021). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL, constituting up to 40% of all cases. In the United States, the estimated incidence of DLBCL is 7 per 100,000 persons. DLBCL is aggressive, and many patients have advanced disease at diagnosis (Horvat et al, 2018). The 5-year relative survival rate is 63.9%, dropping to only 34% for Stage IV disease (National Cancer Institute, 2021). While R-CHOP (rituximab/cyclophosphamide/doxorubicin/hydrochloride/vincristine sulfate/prednisone) remains first-line therapy, additional options, including monoclonal antibodies and antibody-drug conjugates, are being investigated for relapsed/refractory DLBCL (NCCN, 2021; Wang et al, 2020). It is vitally important for oncology nurses to gain up-to-date knowledge of guideline recommendations, clinical research advances, and adverse event management in order to provide optimal care to patients with this condition.


Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with diffuse large B-cell lymphoma.


Upon completion of this activity, participants should be able to:

  • Evaluate guideline recommendations for the management of individual patients with advanced diffuse large B-cell lymphoma (DLBCL)

  • Assess emerging data on novel therapies for advanced DLBCL

  • Apply strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for advanced DLBCL

12 views0 comments

Recent Posts

See All

Cancer Equity Colloquium 2024

Now more than ever, the presence of social inequities in healthcare is evident. This two-day, hybrid event, the Cancer Equity Colloquium, will address the diverse issues that underlie cancer inequitie


bottom of page